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urinary ﬂow rate. Physician’s diagnosis according to their expe-
rience, was recorded after each step A descriptive analysis was
conducted and validity and concordance were measured between
strategies. RESULTS: A total of 356 patients, mean age (SD) of
65.2 (8.4) years, with suspected BPH participated in the study.
Sensitivity, speciﬁcity, positive predictive value and negative pre-
dictive value were 91%, 65%, 95% and 50%, respectively. Per-
centage of agreement and kappa index between initial and ﬁnal
diagnosis were 87.9% and 0.5, respectively. CONCLUSIONS:
Concordance between initial diagnosis based on medical history,
I-PSS questionnaire, DRE and PSA with ﬁnal diagnosis of BPH
was high. This group of diagnostic procedures may be recom-
mended for BPH initial diagnosis in daily practice.
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OBJECTIVES: Despite current diabetes guidelines recommend-
ing increasingly stringent HbA1c targets, in the US approxi-
mately 60% of subjects are not controlled to target HbA1c
< 7%, with a typical 5-year delay. The purpose of this analysis
was to evaluate the effect of early achievement of glycemic
control on diabetes-related complications and costs.
METHODS: The Archimedes model was used to conduct a sim-
ulated clinical trial using patient-speciﬁc US NHANES data to
determine patient characteristics, current levels of glycemic
control and other CAD risk factors in people with diabetes. Sub-
jects with HbA1c > 7% were randomly assigned to four man-
agement strategies: status quo (SQ; maintaining current levels of
HbA1c but good compliance to guidelines for other CAD risk
factors), and reaching mean HbA1c < 7% within 6 months (MO),
12MO, or 24MO. The analysis focused on microvascular out-
comes. RESULTS: The model predicted that reducing HbA1c to
<7% in currently uncontrolled subjects would reduce the risk of
microvascular disease compared with SQ. Reaching HbA1c < 7%
within 6MO would reduce the 20-year risks of proteinuria
(52%), ESRD (44%, approximately 20,000 US cases prevented
p.a.), eye surgery (73%) and blindness (73%, approximately
17,500 cases prevented) compared with SQ. However, compared
with reaching HbA1c < 7% within 6MO, delaying to 24MO
increases these risks by 15%, 16%, 41% and 47%, respectively,
resulting in 3900 and 3000 more cases of ESRD and blindness,
respectively. Reaching target within 6MO would save approxi-
mately $2.3 billion p.a. compared with SQ. Delaying reaching
HbA1c < 7% to 24MO decreases these savings by approximately
$430 million. Beneﬁts were greater in patients with mean base-
line HbA1c > 9%. CONCLUSIONS: The Archimedes model pre-
dicts that in uncontrolled subjects, achieving HbA1c < 7% within
6MO would have important effects on microvascular outcomes
and costs. Delaying control to 24MO would reduce the amount
of beneﬁt gained. Bringing currently uncontrolled people into
control is important and should be achieved as rapidly as clini-
cally feasible.
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OBJECTIVES: Several trials of atomoxetine for the treatment of
attention deﬁcit hyperactivity disorder (ADHD) have employed
an active comparator arm of methylphenidate (MPH). This study
estimated efﬁcacy of atomoxetine and MPH in treating children
and adolescent with ADHD using combined patient-level data
from multiple trials. METHODS: Five randomized atomoxetine
trials contained an active comparator arm of MPH. Pooling of
all available data resulted in total 1078 patients, with 562 on
atomoxetine, 327 on MPH, and 189 on placebo. Because trials
excluded known non-responders to stimulant, stimulant exposed
patients may have a bias in favor of MPH. Subgroup analyses
were performed by stimulant history. The meta-regression is set
up as logistic regression for response. Response was deﬁned as
a ≥25% reduction in ADHD Rating Scale. In addition to treat-
ments, patient age, sex, duration of therapy, and trial effects were
controlled for. Random effect model was also estimated, but
ﬁxed effect was chosen. RESULTS: Response rates for stimulant
naïve patients were: 70.51% for atomoxetine, 77.27% for MPH,
and 41.46% for placebo. Response rate for each active treatment
was signiﬁcant, and signiﬁcantly different from placebo (p <
0.001). However, the two treatments were not statistically dif-
ferent by difference in means test (p = 0.069). In the exposed
group, response rates were: 62.17% for atomoxetine, 70.03%
for MPH, and 29.42% for placebo. Response rate for each active
treatment was signiﬁcant, and signiﬁcantly different from
placebo (p < 0.001). Difference between the two treatments, yet
again, was not statistically signiﬁcant (p = 0.214). CONCLU-
SION: To improve power and precision in the estimate, this
study pooled all available patient-level data from ﬁve random-
ized trials, and estimated response rate using the meta-regression
method. Efﬁcacy of atomoxetine and MPH were signiﬁcantly dif-
ferent from placebo. While response rate was higher for MPH,
response rates of the two active treatments were not statistically
different from each other.
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OBJECTIVE: To identify independent risk factors for renal
impairment in HRPC patients receiving ZA, we compared 
logistic regression and Cox proportional hazards models.
METHODS: A comprehensive medical record review was per-
formed, using electronic databases and paper records, in a large
tertiary oncology center. Inclusion criteria: ≥18 years, actively
treated, HRPC with BM, at least one ZA infusion (from 12/1999
to 4/2005), and at least one creatinine reading before and after
ﬁrst ZA infusion. Renal impairment was deﬁned as an increase
of ≥0.5mg/dL and ≥1.0mg/dL over baseline serum creatinine if
baseline was <1.4mg/dL and ≥1.4mg/dL, respectively; or any
doubling of baseline creatinine. Risk factor analysis was by logis-
tic regression with time adjustment, and by Cox model for time-
related binary outcome data. RESULTS: Among the 122 eligible
patients (mean age = 70.1), mean ZA treatment lasted 367.2 days
(mean 10.7 infusions per patient). About 59% of patients dis-
continued ZA; 21% due to renal complications. Twenty-nine
patients (23.8%, 95% CI: 16.2–31.3%) had renal impairment
during treatment; this is higher than previously reported in clin-
ical trials. Renal risk increased with extended ZA therapy (<6
months: 22.5%; ≥12 months: 23.5%; ≥24 months: 31.3%) and
